OTCMKTS:SHTDF Sinopharm Group (SHTDF) Stock Price, News & Analysis $2.35 0.00 (0.00%) As of 04/30/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartShort InterestBuy This Stock About Sinopharm Group Stock (OTCMKTS:SHTDF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sinopharm Group alerts:Sign Up Key Stats Today's Range$2.35▼$2.3550-Day Range$2.15▼$2.4552-Week Range$1.97▼$2.94VolumeN/AAverage Volume2,500 shsMarket CapitalizationN/AP/E Ratio2.35Dividend Yield11.06%Price TargetN/AConsensus RatingN/A Company OverviewSinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.Read More… Sinopharm Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreSHTDF MarketRank™: Sinopharm Group scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Sinopharm Group. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sinopharm Group is 2.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.77.Price to Earnings Ratio vs. SectorThe P/E ratio of Sinopharm Group is 2.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.58. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverSinopharm Group has a short interest ratio ("days to cover") of 11460.6, which indicates bearish sentiment.Change versus previous monthShort interest in Sinopharm Group has recently decreased by 41.33%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldSinopharm Group pays a meaningful dividend of 1.11%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthSinopharm Group does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Sinopharm Group is 26.05%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Sinopharm Group's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverSinopharm Group has a short interest ratio ("days to cover") of 11460.6, which indicates bearish sentiment.Change versus previous monthShort interest in Sinopharm Group has recently decreased by 41.33%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News SentimentN/A News SentimentSinopharm Group has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Sinopharm Group this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sinopharm Group insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 16.47% of the stock of Sinopharm Group is held by institutions.Read more about Sinopharm Group's insider trading history. Receive SHTDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sinopharm Group and its competitors with MarketBeat's FREE daily newsletter. Email Address SHTDF Stock News HeadlinesSinopharm Group: The Focus Is On Working Capital And ProfitabilityNovember 22, 2024 | seekingalpha.comSinopharm Group’s Asset Growth Boosts Investor ConfidenceOctober 28, 2024 | markets.businessinsider.comBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.May 1, 2025 | Crypto 101 Media (Ad)Sinopharm Group Co. Reports Mixed Financial ResultsOctober 28, 2024 | markets.businessinsider.comSinopharm Group Shares Fall as Higher Costs Cut Into Quarterly ProfitApril 29, 2024 | marketwatch.comSinopharm Group Co Ltd ADR X2S1April 6, 2024 | morningstar.comSinopharm Group Co Ltd 01099February 21, 2024 | morningstar.comSinopharm Group Co Ltd X2SJanuary 30, 2024 | morningstar.comSee More Headlines SHTDF Stock Analysis - Frequently Asked Questions How have SHTDF shares performed this year? Sinopharm Group's stock was trading at $2.49 at the beginning of 2025. Since then, SHTDF shares have decreased by 5.6% and is now trading at $2.35. View the best growth stocks for 2025 here. How do I buy shares of Sinopharm Group? Shares of SHTDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical Distribution Sub-IndustryPersonal Services Current SymbolOTCMKTS:SHTDF CIK1556605 Webir.sinopharmgroup.com.cn Phone86-21-2305-2666FaxN/AEmployees115,959Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio2.35 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (OTCMKTS:SHTDF) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinopharm Group Co. Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinopharm Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.